José M. Carbó Marqués

Experienced biomedical scientist and strategic consultant with over a decade of work in oncology R&D, combining academic and biotech industry expertise. Proven track record in translational research, preclinical drug development, and competitive intelligence in clinical-stage oncology. Adept at bridging science and business, supporting data-driven decision-making, clinical trial design, and engagement with KOLs. Committed to innovation and bringing forward impactful cancer therapies

• Novel family of lysosomotropic tetracyclic compounds for treating leukemia; Cancers (Basel), 03/22/23, 15, 6, 1912
• Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment, Cancer Res, 02/15/21, 81, 4
• Full list available at my ORCID (https://orcid.org/0000-0001-8301-5360)

CT.gov, PubMed, UCSC Genome Browser, MS365 (PowerPoint, Excel, Word), GraphPad, FlowJo, ImageJ, Flow cytometry, in vivo models (NSG mice), gene expression profiling, ChIP, Seahorse, Zoom, Teams

• Spanish, Native
• Catalan, Native
• English, Fluent (spoken & written)

• Co-inventor of international patent: Compositions for the treatment of leukemia (PCT/EP2021/082705).